Rocket Pharmaceuticals, Inc. Current Assets
Rocket Pharmaceuticals, Inc. (RCKT) had Current Assets of $289.55 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AssetsCurrent · last filed 2026-08-10
- 2026-06-30: Assets, Current $289.55M.
- 2026-03-31: Assets, Current $149.83M.
- 2025-12-31: Assets, Current $192.73M.
- 2025-09-30: Assets, Current $227.68M.
| Period end | Assets, Current | Assets, Current as first filed |
|---|---|---|
| 2026-06-30 | $289.55M 10-Q · filed 2026-08-10 | |
| 2026-03-31 | $149.83M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $192.73M 10-Q · filed 2026-08-10 | |
| 2025-09-30 | $227.68M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $277.15M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $324.49M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $378.18M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $241.75M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $292.73M 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $345.16M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $378.22M 10-K · filed 2025-02-27 | |
| 2023-09-30 | $446.87M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $312.07M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $338.03M 10-Q · filed 2023-05-05 | |
| 2022-12-31 | $364.06M 10-K · filed 2024-02-27 | |
| 2022-09-30 | $311.13M 10-Q · filed 2022-11-04 | |
| 2022-06-30 | $325.77M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $353.85M 10-Q · filed 2022-05-06 | |
| 2021-12-31 | $392.06M 10-K · filed 2023-02-28 | |
| 2021-09-30 | $425.07M 10-Q · filed 2021-11-05 | |
| 2021-06-30 | $430.43M 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $471.82M 10-Q · filed 2021-05-10 | |
| 2020-12-31 | $487.35M 10-K · filed 2022-02-28 | |
| 2020-09-30 | $233.21M 10-Q · filed 2020-11-06 | |
| 2020-06-30 | $255.44M 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $279.81M 10-Q · filed 2020-05-08 | |
| 2019-12-31 | $307.75M 10-K · filed 2021-03-01 | |
| 2019-09-30 | $245.59M 10-Q · filed 2019-11-08 | |
| 2019-06-30 | $263.63M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $199.62M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $209.09M 10-K · filed 2020-03-06 | |
| 2018-09-30 | $128.82M 10-Q · filed 2018-11-09 | |
| 2018-06-30 | $134.61M 10-Q · filed 2018-08-14 | |
| 2018-03-31 | $184.83M 10-Q · filed 2018-05-11 | |
| 2017-12-31 | $18.95M 10-K · filed 2019-03-08 | $101.05M 10-K · filed 2018-03-07 |
| 2017-09-30 | $103.87M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $109.82M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $116.63M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $128.35M 10-K · filed 2018-03-07 | |
| 2016-09-30 | $138.92M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $98.70M 10-Q · filed 2016-08-10 | |
| 2016-03-31 | $103.25M 10-Q · filed 2016-05-11 | |
| 2015-12-31 | $112.37M 10-K · filed 2017-03-16 | |
| 2015-09-30 | $119.22M 10-Q · filed 2015-11-12 | |
| 2015-06-30 | $49.48M 10-Q · filed 2015-08-07 | |
| 2015-03-31 | $53.44M 10-Q · filed 2015-05-14 | |
| 2014-12-31 | $3.67M 10-K · filed 2016-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |